2025-12-18T13:04:21.021718+0530 | INFO | Session: 64e3b6c5-4efb-49b7-8065-d352ff775385 | User: What's the recommended dose for Metformin? | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:04:41.883643+0530 | INFO | Session: 64e3b6c5-4efb-49b7-8065-d352ff775385 | User: What AEs are reported for Pembrolizumab in melanoma? | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:04:57.167419+0530 | INFO | Session: 64e3b6c5-4efb-49b7-8065-d352ff775385 | User: Any cautions in the NSCLC label? | Source: Pharma_Clinical_Trial_Notes.docx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:05:54.735969+0530 | INFO | Session: 64e3b6c5-4efb-49b7-8065-d352ff775385 | User: What about dosing frequency for that? | Source: none | Retrieved: 0 | Clarification: True | Unknown: False | Safety: False
2025-12-18T13:06:30.356387+0530 | INFO | Session: 64e3b6c5-4efb-49b7-8065-d352ff775385 | User: What about dosing frequency for that? | Source: none | Retrieved: 0 | Clarification: True | Unknown: False | Safety: False
2025-12-18T13:06:36.268122+0530 | INFO | Session: 64e3b6c5-4efb-49b7-8065-d352ff775385 | User: Nivolumab | Source: Pharma_Clinical_Trial_AllDrugs.xlsx, Pharma_Clinical_Trial_Notes.docx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:06:50.631533+0530 | INFO | Session: 64e3b6c5-4efb-49b7-8065-d352ff775385 | User: Provide dosage adjustment recommendations for renal impairment. | Source: none | Retrieved: 0 | Clarification: True | Unknown: False | Safety: False
2025-12-18T13:09:39.631631+0530 | INFO | Session: 2ee8699b-4f2c-4769-aa33-ce005028daa2 | User: What's the recommended dose for Metformin? | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:09:51.345979+0530 | INFO | Session: 3d8092b4-1179-4009-b122-efe6993df9f1 | User: What AEs are reported for Pembrolizumab in melanoma? | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:10:43.482092+0530 | INFO | Session: aa7af8f2-0409-44f6-9c76-23e84760c50c | User: Any cautions noted for Nivolumab? | Source: Pharma_Clinical_Trial_Notes.docx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:10:55.262692+0530 | INFO | Session: aa7af8f2-0409-44f6-9c76-23e84760c50c | User: Whatâ€™s the recommended dose for Metformin | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:11:09.513313+0530 | INFO | Session: aa7af8f2-0409-44f6-9c76-23e84760c50c | User: What AEs are reported for Pembrolizumab in melanoma? | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:11:19.886928+0530 | INFO | Session: aa7af8f2-0409-44f6-9c76-23e84760c50c | User: For Imatinib, how severe are common hematological AEs? | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:11:36.769672+0530 | INFO | Session: aa7af8f2-0409-44f6-9c76-23e84760c50c | User: Any cautions in the NSCLC label? | Source: Pharma_Clinical_Trial_Notes.docx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:11:56.363208+0530 | INFO | Session: aa7af8f2-0409-44f6-9c76-23e84760c50c | User: What about dosing frequency for that? | Source: none | Retrieved: 0 | Clarification: True | Unknown: False | Safety: False
2025-12-18T13:12:13.595640+0530 | INFO | Session: aa7af8f2-0409-44f6-9c76-23e84760c50c | User: Nivolumab | Source: Pharma_Clinical_Trial_AllDrugs.xlsx, Pharma_Clinical_Trial_Notes.docx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T13:12:25.903613+0530 | INFO | Session: aa7af8f2-0409-44f6-9c76-23e84760c50c | User: Provide dosage adjustment recommendations for renal impairment. | Source: none | Retrieved: 0 | Clarification: True | Unknown: False | Safety: False
